AI Maverick Intel Inc. (OTCID: AIMV) has entered into a definitive share purchase agreement to acquire Heal Access Canada Inc., an artificial intelligence healthcare technology company, from its controlling stockholder, HEAL Group Holdings Inc. The acquisition, announced on Oct. 12, 2026, marks a significant step for AIMV as it seeks to grow through AI and technology-enabled healthcare businesses. The deal, valued at $5 million in consideration through a secured, two-year promissory note bearing 10% annual interest, plus 20 million exchangeable shares convertible into AIMV common stock, underscores the company's commitment to expanding its footprint in the rapidly evolving AI healthcare sector. For investors, this acquisition could position AIMV as a key player in integrating AI into clinical workflows, potentially driving long-term value as healthcare systems increasingly adopt digital solutions.
Heal Access operates an AI-powered healthcare intelligence platform that integrates patient information and supports clinical workflows. The platform is already operational in five countries and serves more than 118,000 patients, demonstrating its scalability and real-world impact. By acquiring Heal Access, AIMV gains immediate access to a proven technology and an established patient base, which could accelerate its revenue growth and market penetration. The transaction, however, remains subject to several closing conditions, including at least $6 million in financing and independent special committee ratification. AIMV expects to use commercially reasonable efforts to complete the required financing by Dec. 31, 2026, with either party permitted to terminate the agreement if the transaction has not closed by Feb. 28, 2027. The company will also assume approximately $6.4 million in existing obligations owed by Heal Access and its subsidiaries to HEAL Group and affiliates.
A critical implication of the deal is the potential change in control. Upon conversion of all exchangeable shares, HEAL Group would hold approximately 80.1% of AIMV common stock before accounting for any shares issued in the financing. This substantial ownership stake could give HEAL Group significant influence over AIMV's strategic direction, potentially aligning the company even more closely with HEAL Group's healthcare-focused vision. AIMV clarified that its Sept. 21 announcement incorrectly described the acquisition agreement as definitive, noting that the binding agreement was signed Oct. 12, 2026. This correction highlights the importance of precise communication in regulatory filings, especially for investors relying on accurate timelines.
The acquisition aligns with AIMV's stated intent to grow through Heal Access and through further acquisitions of AI and technology-enabled healthcare businesses, including opportunities available to it under its right of first refusal agreement with HEAL Group Holdings Inc., its controlling stockholder. For the broader market, this move signals continued consolidation in the AI healthcare space, where companies are racing to integrate AI into patient care and clinical decision-making. As AIMV's common stock is quoted on the OTCID Basic Market under the symbol "AIMV," investors can monitor the latest news and updates relating to the company in its newsroom at http://ibn.fm/AIMV.
The deal's success hinges on securing financing and meeting closing conditions, but if completed, it could transform AIMV into a more formidable competitor in AI healthcare. The full press release is available at https://ibn.fm/1XVOv. As part of the broader communications ecosystem, TechMediaWire, a specialized platform focused on pioneering companies driving the future of technology, operates within the Dynamic Brand Portfolio @ IBN, delivering access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For more details on TechMediaWire's offerings, visit TechMediaWire.
